Anidulafungin

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neutropenia

Conditions

Neutropenia

Trial Timeline

Jul 1, 2003 → Jun 1, 2004

NCT ID

NCT00056381

About Anidulafungin

Anidulafungin is a phase 1/2 stage product being developed by Pfizer for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00056381. Target conditions include Neutropenia.

What happened to similar drugs?

8 of 18 similar drugs in Neutropenia were approved

Approved (8) Terminated (5) Active (8)

✅MicafunginAstellas PharmaApproved

❌HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3

✅Imipenem + ImipenemMerckApproved

✅Ceftolozane-Tazobactam + MeropenemMerckApproved

✅Ceftolozane-tazobactam IVMerckApproved

❌Daptomycin + DaptomycinMerckPhase 3

🔄pegfilgrastimAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01202253	Pre-clinical	Completed	Feb 1, 2011	May 1, 2011	Candidiasis
NCT00934934	Phase 2	Terminated	Apr 1, 2010	Aug 1, 2012	Ventilator Associated Pneumonia
NCT01053884	Phase 2	Terminated	Oct 1, 2009	Sep 1, 2011	Hematologic Malignancies
NCT00537329	Phase 3	Completed	Jan 1, 2008	Mar 1, 2009	Candidemia
NCT00056381	Phase 1/2	Completed	Jul 1, 2003	Jun 1, 2004	Neutropenia

Competing Products

20 competing products in Neutropenia

See all competitors

Product	Company	Stage	Hype Score
Micafungin	Astellas Pharma	Approved	39
pegfilgrastim	Kyowa Kirin	Phase 2	35
HHPG-19K Injection	Jiangsu Hengrui Medicine	Phase 3	32
caspofungin acetate + Comparator: AmBisome	Merck	Phase 2	35
Imipenem + Imipenem	Merck	Approved	43
Posaconazole IV solution + Posaconazole powder for oral suspension	Merck	Phase 1	29
Ceftolozane-Tazobactam + Meropenem	Merck	Approved	50
Ceftolozane-tazobactam IV	Merck	Approved	35
Daptomycin + Daptomycin	Merck	Phase 3	32
pegfilgrastim	Amgen	Phase 3	40
Neulasta (pegfilgrastim)	Amgen	Approved	43
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)	Gilead Sciences	Approved	35
Filgrastim Hospira (US) + US-approved Neupogen®	Pfizer	Phase 1	29
HSP-130 + US-approved Neulasta + EU-approved Neulasta	Pfizer	Phase 1	29
linezolid + vancomycin	Pfizer	Phase 3	40
Nivestim®	Pfizer	Pre-clinical	18
Antibacterial agent for the treatment of febrile neutropenia	Pfizer	Pre-clinical	26
Voriconazole	Pfizer	Phase 1/2	32
Filgrastim Hospira (US) + U.S.-approved Neupogen®	Pfizer	Phase 1	29
ciprofloxacin + cefepime	Bayer	Phase 3	37